Company: PETVW
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001493152-25-011967
Chunk: 55

Company: PetVivo Holdings, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 55
---
 were $340,513 and $387,515 for the three months ended June 30, 2025 and 2024, respectively.
The decrease was primarily related to decreased clinical studies due to tight cash flow constraints.

Operating
Loss. As a result of the foregoing, our operating loss was $1,844,317 and $2,044,432 for the three months ended June 30, 2025
and 2024, respectively. The decrease was related to cost-cutting initiatives in general and administrative and research and development
expenses.

Other
Income (Expense). Other income (expense) was ($466,720) for the three months ended June 30, 2025 compared to other expense of
($2,631) for the three months ended June 30, 2024. Other income (expense) in 2025 consisted of unrealized loss on change in derivative
liabilities and loss on disposal of assets. Other income (expense) in 2024 consisted of interest expense.

Net
Loss. Our net loss for the three months ended June 30, 2025 was $2,311,037 or ($0.09) per share as compared to a net loss of
$2,047,063 or ($0.11) per share for the three months ended June 30, 2024. The increase was primarily related to the loss on change in
derivative liabilities and the loss on disposal of assets. The weighted average number of shares outstanding was 24,302,790 compared
to 18,683,975 for the three months ended June 30, 2025 and 2024, respectively.

LIQUIDITY
AND CAPITAL RESOURCES

As
of June 30, 2025, our current assets were $4,400,859, including $3,303,844 in cash and cash equivalents. In comparison, our current liabilities
as of that date were $3,117,433 including $1,590,770 of accounts payable and accrued expenses. Our working capital as of June 30, 2025
was $1,283,426.

The
Company has continued to realize losses from operations. As a result of our private placement offering with proceeds of $5,000,000 from
the sale of Series B convertible preferred stock, we do not believe we will have sufficient cash to meet our anticipated operating costs
and capital expenditure requirements for at least the next twelve months. We will need to raise